SCHEMBL23588103

SCHEMBL23588103

CCOP(=O)(OCC)C(Cc1nc(-c2ccc(CCC3CC3)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 8/20 0.41
CYP2C19 P33261 3/20 0.38
TSHR P16473 3/20 0.38
GPR119 Q8TDV5 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 2/20 0.38
ALOX15 P16050 1/20 0.38
HTT P42858 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RAB9A P51151 2/20 0.37
FFAR1 O14842 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 2/20 0.37
RECQL P46063 1/20 0.37
MITF O75030 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801989 0.92 SPHK1 (0.40) SPHK1CYP2C19TSHRGPR119SMN1; SMN2
SCHEMBL25804667 0.89 SPHK1 (0.43) SPHK1CYP2C19TSHRSMN1; SMN2TP53
SCHEMBL23578218 0.88 SPHK1 (0.47) SPHK1FFAR1
SCHEMBL23588176 0.87 S1PR4 (0.40) CYP2C19TSHRSMN1; SMN2TP53ALDH1A1
SCHEMBL23578053 0.85 SPHK1 (0.38) SPHK1CYP2C19TSHRTP53ALDH1A1
SCHEMBL25807564 0.85 TP53 (0.39) CYP2C19TSHRGPR119SMN1; SMN2TP53
SCHEMBL25804401 0.85 TSHR (0.47) CYP2C19TSHRSMN1; SMN2TP53ALDH1A1
SCHEMBL23588293 0.85 HTT (0.40) CYP2C19TSHRSMN1; SMN2TP53ALDH1A1
SCHEMBL23588294 0.85 TP53 (0.39) CYP2C19TSHRGPR119SMN1; SMN2TP53
SCHEMBL23578561 0.84 GPR119 (0.39) CYP2C19TSHRGPR119SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 CN disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 SPHK1 3875/4885CYP2C19 2454/4885TSHR 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.